{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T11:20:18Z","timestamp":1788002418625,"version":"build-2784847793"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The nonclinical development of T-cell receptor (TCR)\u2013based therapeutics is uniquely challenged by the human-exclusive specificity of the peptide-HLA target, rendering conventional animal models unsuitable for safety assessment. To support first-in-human (FIH) studies in patients with solid tumors with the novel TCR-like T Cell Bispecific (TCB) antibody MAGE-A4-TCB, targeting the MAGE-A4 peptide presented by HLA-A*02:01 and engaging T-cells via the CD3\u03f5 chain, we implemented a comprehensive, prediction-independent safety strategy relying on New Approach Methodologies (NAMs). This approach utilized 21 human cellular systems, including 2D and 3D\n                    <jats:italic>in vitro<\/jats:italic>\n                    models of vital organs (such as liver, heart, kidney, and lung), co-cultured with allogeneic peripheral blood mononuclear cells to identify potential off-target toxicity and a whole blood assay for cytokine release risk assessment. The concentration-effect relationship and Minimal Anticipated Biological Effect Level (MABEL) were established using the A375 cancer cell line, chosen for its comparable sensitivity to ovarian carcinoma organoids, which were the most sensitive out of 22 tested tumor organoids. Nonclinical testing demonstrated an absence of off-target reactivity in vital organs, though the whole blood assay predicted cytokine release syndrome as the primary risk. The calculated FIH starting dose was safe in the subsequent Phase I study (NCT05129280), and the most commonly reported adverse events were treatment-related skin and subcutaneous tissue disorders (73% of patients). These skin-related adverse events, which appeared in contradiction to the initial\n                    <jats:italic>in vitro<\/jats:italic>\n                    results in skin co-culture models, were hypothesized to be driven by the target-independent activation capability of the UCHT1-based CD3 binder, potentially enhanced in patients with a systemic pro-inflammatory profile. This study provides a translational framework for TCR-based immunotherapies, demonstrating the successful application of NAMs to define a safe starting dose while highlighting the critical need for refining these methodologies to accurately predict complex, systemic immune-related adverse events, particularly those involving barrier organs.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1736584","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:00:02Z","timestamp":1776416402000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with an in vitro-based safety approach"],"prefix":"10.3389","volume":"17","author":[{"given":"Angelique","family":"Augustin","sequence":"first","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Avignon","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Boetsch","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Breous-Nystrom","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Broders","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG","place":["Schlieren, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauriane","family":"Cabon","sequence":"additional","affiliation":[{"name":"Roche Institute of Human Biology, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dernick","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Durr","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miro Julian","family":"Eigenmann","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Fischer","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Flinn","sequence":"additional","affiliation":[{"name":"Roche Early Development Safety, Roche Products Ltd.","place":["Welwyn Garden City, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regine","family":"Gerard","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Giusti","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG","place":["Schlieren, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolche","family":"Gjorevski","sequence":"additional","affiliation":[{"name":"Roche Institute of Human Biology, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Juergen","family":"Grote","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH","place":["Penzberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"H\u00e4usermann","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Hobi","sequence":"additional","affiliation":[{"name":"AlveoliX AG, Swiss Organs-on-Chip Innovation","place":["Bern, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Husar","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Juglair","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Patrick","family":"Keiser","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG","place":["Schlieren, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Keshelava","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG","place":["Schlieren, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kustermann","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Marban-Doran","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Marrer-Berger","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Martinez","family":"Quetglas","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG","place":["Schlieren, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Micallef","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Matheis","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ortiz Franyuti","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liudmila","family":"Polonchuk","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Raggi","sequence":"additional","affiliation":[{"name":"AlveoliX AG, Swiss Organs-on-Chip Innovation","place":["Bern, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Roller","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Ruffiner","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Sadok","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulun","family":"Saylan","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Schaub","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9e","family":"Schubert","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyajit","family":"Shetage","sequence":"additional","affiliation":[{"name":"Roche Pharma Development, Regulatory, Roche Products Ltd.","place":["Welwyn Garden City, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Stokar-Regenscheit","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje-Christine","family":"Walz","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Weinzierl","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG","place":["Schlieren, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Wolowski","sequence":"additional","affiliation":[{"name":"Roche Pharma Development, Data Sciences, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Zihlmann","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01206-x","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020287","article-title":"Overcoming challenges for CD3-bispecific antibody therapy in solid tumors","volume":"13","author":"Middelburg","year":"2021","journal-title":"Cancers Bsl"},{"key":"B4","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","article-title":"T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome","volume":"22","author":"Klebanoff","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00073-7","article-title":"T cell receptor therapeutics hit the immuno-oncology stage","volume":"21","author":"Kingwell","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/jci130562","article-title":"Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA","volume":"130","author":"Holland","year":"2020","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-1247","article-title":"Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585385","article-title":"Empirical and rational design of T cell receptor-based immunotherapies","volume":"11","author":"Jones","year":"2020","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21956\/openreseurope.14914.r27773","article-title":"An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules","volume":"13","author":"Harper","year":"2018","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12662","article-title":"A modeling framework to characterize cytokine release upon T-cell-engaging bispecific antibody treatment: Methodology and opportunities","volume":"12","author":"Chen","year":"2019","journal-title":"Clin Transl Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.60","article-title":"Case report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor","volume":"23","author":"van den Berg","year":"2015","journal-title":"Mol Ther"},{"key":"B15","volume-title":"ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals","year":"1997"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2015.07.022","article-title":"Impact analysis of ICH S9 on non-clinical development of anticancer drugs","volume":"73","author":"Bonelli","year":"2015","journal-title":"Regul Toxicol Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061779","article-title":"The melanoma-associated antigen family A (MAGE-A): a promising target for cancer immunotherapy","volume":"15","author":"Alsalloum","year":"2023","journal-title":"Cancers Bsl"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/cancers17030413","article-title":"Adoptive T cell therapy targeting MAGE-A4","volume":"17","author":"Chandora","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1484182","article-title":"Mapping MAGE-A4 expression in solid cancers for targeted therapies","volume":"15","author":"Habigt","year":"2025","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/9.7.617","article-title":"Knobs-into-holes\u201d engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng Des Sel"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/iai.71.12.6775-6783.2003","article-title":"Monoclonal antibodies human T cell subsets","volume":"128","author":"Burns","year":"1982","journal-title":"J Immunol"},{"key":"B25","article-title":"Identification heavy chain residues humanized anti-CD3 antibody variant determine binding affinity","volume":"154","author":"Zhu","year":"1995","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1462429","article-title":"Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach","volume":"10","author":"Betts","year":"2018","journal-title":"MAbs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pmx Syst Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00637-2","article-title":"A novel approach for quantifying the pharmacological activity of T-cell engagers utilizing in vitro time course experiments and streamlined data analysis","volume":"24","author":"Van De Vyver","year":"2021","journal-title":"AAPS J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2017.09.001","article-title":"An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection","volume":"90","author":"Saber","year":"2017","journal-title":"Regul Toxicol Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011201)92:11<2778::aid-cncr10125>3.0.co;2-s","article-title":"MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors","volume":"92","author":"Aubry","year":"2001","journal-title":"Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21616","article-title":"Expression of MAGE-A4 and MAGE-C1 tumor-associated antigen in benign and Malignant thyroid diseases","volume":"33","author":"Melo","year":"2011","journal-title":"Head Neck"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/2472555219897567","article-title":"New advances in cell microarray technology to expand applications in target deconvolution and off-target screening","volume":"25","author":"Freeth","year":"2020","journal-title":"SLAS Discov"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1038\/s41467-024-47062-5","article-title":"The physiological interactome of TCR-like antibody therapeutics in human tissues","volume":"15","author":"Marrer-Berger","year":"2024","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006290","article-title":"Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies","volume":"11","author":"Magr\u00e9","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.101","article-title":"Organoid co-culture models of the tumor microenvironment promote precision medicine","volume":"3","author":"Gu","year":"2024","journal-title":"Cancer Innov"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054366","article-title":"Separate developmental programs for HLA-A and -B cell surface expression during differentiation from embryonic stem cells to lymphocytes, adipocytes and osteoblasts","volume":"8","author":"Sabir","year":"2013","journal-title":"PloS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010900","article-title":"Impaired cell surface expression of HLA-B antigens on mesenchymal stem cells and muscle cell progenitors","volume":"5","author":"Isa","year":"2010","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1101\/318444","article-title":"Long-term expanding human airway organoids for disease modeling","volume":"38","author":"Sachs","year":"2019","journal-title":"EMBO J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116214","article-title":"Organoids as models of immune-organ interaction","volume":"44","author":"Harter","year":"2025","journal-title":"Cell Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.stem.2024.04.018","article-title":"Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells","volume":"31","author":"Maulana","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pharmtox-061724-080621","article-title":"Opportunities for microphysiological systems in toxicity testing of new drug modalities","volume":"65","author":"Maulana","year":"2025","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5919","article-title":"Pre-treatment comorbidities, C-reactive protein and eosinophil count, and immune-related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entities","volume":"12","author":"Mehra","year":"2023","journal-title":"Cancer Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1683533","article-title":"Combining immune-related adverse events and inflammatory profiles enhances prognostic accuracy in metastatic melanoma under PD-1-based therapy","volume":"16","author":"Garmpis","year":"2025","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700199","article-title":"A novel method for the isolation of skin resident T cells from normal and diseased human skin","volume":"126","author":"Clark","year":"2006","journal-title":"J Invest Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3155546","article-title":"Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites","volume":"20","author":"Kumar","year":"2017","journal-title":"Cell Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1718","article-title":"Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus","volume":"10","author":"Gebhardt","year":"2009","journal-title":"Nat Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"287","DOI":"10.21417\/b76k56","article-title":"CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"B52","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/b978-0-7020-6912-3.00253-6","article-title":"Interfering with the IFN-\u03b3\/CXCL10 pathway to develop new targeted treatments for vitiligo","volume":"3","author":"Rashighi","year":"2015","journal-title":"Ann Transl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00452-4","article-title":"\u03b3\u03b4 T cells in tissue physiology and surveillance","volume":"21","author":"Ribot","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq7248","article-title":"Cancer immunotherapy by \u03b3\u03b4 T cells","volume":"386","author":"Hayday","year":"2024","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07791-5","article-title":"Human organoids with an autologous tissue-resident immune compartment","volume":"633","author":"Recaldin","year":"2024","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2025.02.27.640440","DOI":"10.1101\/2025.02.27.640440","article-title":"Human lung alveolar model with an autologous innate and adaptive immune compartment","author":"Steinacher","year":"2025"},{"key":"B57","volume-title":"Adaptimmune announces U.s. fda acceptance of biologics license application for Afami-cel for the treatment of advanced synovial sarcoma with priority review","year":"2024"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1891\/9780826148537.0025","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D\u2019Angelo","year":"2024","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2020.122856","article-title":"In vitro-in silico-based probabilistic risk assessment of combined exposure to bisphenol A and its analogues by integrating ToxCast high-throughput in vitro assays with in vitro to in vivo extrapolation (IVIVE) via physiologically based pharmacokinetic (PBPK) modeling","volume":"399","author":"Lin","year":"2020","journal-title":"J Haz Mater"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.06.013","article-title":"Cellular neonatal Fc receptor recycling efficiencies can differentiate target-independent clearance mechanisms of monoclonal antibodies","volume":"113","author":"Bryniarski","year":"2024","journal-title":"J Pharm Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.07.009","article-title":"Utility of cellular measurements of non-specific endocytosis to assess the target-independent clearance of monoclonal antibodies","volume":"113","author":"Bryniarski","year":"2024","journal-title":"J Pharm Sci"},{"key":"B62","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41467-018-03061-x","article-title":"A human endothelial cell-based recycling assay for screening of FcRn targeted molecules","volume":"9","author":"Grevys","year":"2018","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1683432","article-title":"Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis","volume":"12","author":"Kraft","year":"2020","journal-title":"MAbs"},{"key":"B64","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41698-025-01082-6","article-title":"PharmaFormer predicts clinical drug responses through transfer learning guided by patient derived organoid","volume":"9","author":"Zhou","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-025-00052-8","article-title":"Insights into new approach methodology innovation: an EMA perspective","volume":"24","author":"Edwards","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"B66","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41587-025-02690-0","article-title":"FDA pushes to replace animal testing","volume":"43","year":"2025","journal-title":"Nat Biotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1736584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:00:04Z","timestamp":1776416404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1736584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2026.1736584"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1736584","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"article-number":"1736584"}}